2016
DOI: 10.1530/erc-16-0427
|View full text |Cite
|
Sign up to set email alerts
|

Pushing estrogen receptor around in breast cancer

Abstract: The estrogen receptor-α (herein called ER) is a nuclear sex steroid receptor (SSR) that is expressed in approximately 75% of breast cancers. Therapies that modulate ER action have substantially improved the survival of patients with ER-positive breast cancer, but resistance to treatment still remains a major clinical problem. Treating resistant breast cancer requires co-targeting of ER and alternate signalling pathways that contribute to resistance to improve the efficacy and benefit of currently available tre… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

2
27
0
1

Year Published

2016
2016
2024
2024

Publication Types

Select...
7
1
1

Relationship

2
7

Authors

Journals

citations
Cited by 39 publications
(31 citation statements)
references
References 146 publications
2
27
0
1
Order By: Relevance
“…S6) and HBCx-22 ( Fig. 2) (9,51). It is conceivable that the varying degree of growth inhibition seen with SARM may be attributed to different ER positivity of these models.…”
Section: Discussionmentioning
confidence: 98%
“…S6) and HBCx-22 ( Fig. 2) (9,51). It is conceivable that the varying degree of growth inhibition seen with SARM may be attributed to different ER positivity of these models.…”
Section: Discussionmentioning
confidence: 98%
“…For 26 many patients, the disease is treated effectively by surgery and adjuvant endocrine therapy. 27 Unfortunately, ~35% of patients receiving endocrine therapy relapse with resistant disease, either 28 through inherent resistance to treatment or the emergence of acquired endocrine resistance (1,2). 29 Resistant disease that retains ER positivity is typically managed by treating with additional lines 30 of endocrine therapy.…”
Section: Introductionmentioning
confidence: 99%
“…The role of the ER, which exists as two subtypes transcribed from two distinct genes (Kuiper et al 1996, Kuiper & Gustafsson 1997, Enmark & Gustafsson 1999, ER-A and ER-B (Ascenzi et al 2006), has been extensively studied in breast cancer cell biology. Traditionally, estrogens and ER-A were thought to be the main etiological factors contributing to breast cancer pathogenesis, while the PR was considered only as an indicator of a functional ER in breast cancer tumors, implying that the cancer should be sensitive to endocrine-targeting therapies (Horwitz & McGuire 1975, Carroll et al 2016, Lim et al 2016. However, recent studies have highlighted novel roles for the PR in breast cancer cell biology (Daniel et al 2011, Giulianelli et al 2012, Mohammed et al 2015, Singhal et al 2016.…”
Section: Introductionmentioning
confidence: 99%